Summary Electrochemotherapy is an anti-tumour treatment that utilizes locally delivered electric pulses to increase cytotoxicity of chemotherapeutic drugs. The aim of our study was to determine whether anti-tumour effectiveness of electrochemotherapy with cisplatin is a consequence of increased plasma membrane permeability caused by electroporation that enables cisplatin binding to DNA. For this purpose, anti-tumour effectiveness of electrochemotherapy was evaluated on SA-1 tumours treated with electric pulses 3 min after intravenous injection of cisplatin (4 mg kg -1 ). Anti-tumour effectiveness was correlated with platinum accumulation in tumours and the amount of platinum bound to DNA, as determined by atomic absorption spectrometry. In tumours treated with electrochemotherapy, cell kill was increased by a factor of 20 compared with treatment with cisplatin only, as determined from tumour growth curves. The amount of platinum bound to DNA and platinum content in the tumours treated by electrochemotherapy was approximately two times higher than in cisplatin-treated tumours. Based on our results, we conclude that in vivo application of electric pulses potentiates anti-tumour effectiveness of cisplatin by electroporation that consequently results in cisplatin increased delivery into the cells. In addition, besides electroporation, immune system and tumour blood flow changes could be involved in the observed anti-tumour effectiveness of electrochemotherapy.
Electroporation is a physical method in which high voltage direct current electric pulses cause non-selective plasma membrane permeabilization. This method is widely used for introduction of molecules such as DNA, antibodies, enzymes, dyes and drugs into cells (Orlowski and Mir, 1993) . The use of electric pulses to facilitate delivery of chemotherapeutic drugs into tumour cells was termed electrochemotherapy and was introduced by Okino (Okino and Mohri, 1987) and Mir . Anti-tumour effectiveness of electrochemotherapy with the chemotherapeutic drugs bleomycin and cisplatin has been extensively elaborated on various tumour models in vivo (Sersa et al, 1994 Mir et al, 1995) , and was also demonstrated to be effective in treatment of accessible tumour nodules of various malignancies in cancer patients (Mir et al, 1998; Sersa et al, 1998a) .
The critical intracellular target for cytotoxicity of both cisplatin and bleomycin is DNA. Bleomycin causes single-and doublestranded breaks in DNA, whereas cytotoxicity of cisplatin is believed to be due to the formation of DNA adducts (Chu, 1994; Mir et al, 1996) . Therefore, the cytotoxicity of drugs is dependent on their intracellular concentration and also upon membrane permeability (Chu, 1994; Mir et al, 1996) . It was shown that electroporation of cells in vitro potentiates cytotoxicity of bleomycin by several hundred times (Poddevin et al, 1991) and cytotoxicity of cisplatin up to 70 times . Electroporation of tumour cells in vivo has been demonstrated to potentiate anti-tumour effectiveness of bleomycin and cisplatin several-fold Heller et al, 1995; Sersa et al, 1995) . A high degree of tumour complete responses, as well as tumour cures, were observed at low drug concentrations without systemic toxicity. Studies demonstrating that electroporation increases accumulation of radiolabelled [ 57 Co]bleomycin in the cells in vitro (Poddevin et al, 1991) and tumours in vivo (Belehradek et al, 1994) have already been performed.
Whether anti-tumour effectiveness of electrochemotherapy in vivo is due to the increased cisplatin delivery into the tumour cells, caused by electroporation, has been speculated but not shown. To answer this question, anti-tumour effectiveness of electrochemotherapy on SA-1 tumours in mice, platinum accumulation in the tumours, and the amount of platinum bound to DNA were measured.
MATERIALS AND METHODS

Animals and tumour model
In the experiments, the inbred strain of A/J mice were used, which were purchased from Rudjer Boskovic Institute (Zagreb, Croatia). They were kept at constant room temperature (24°C) with a natural day/night light cycle in a conventional animal colony. Before the experiments, the mice were subjected to an adaptation period of at least 10 days. Female mice in good condition, without fungal or other infections, weighing 20-22 g and 10-12 weeks of age were included in experiments.
The fibrosarcoma SA-1 tumour model (The Jackson Laboratory, Bar Harbor, ME, USA), syngeneic to A/J mice, was used in the study. Tumour cells were obtained from the ascitic form of the tumours in mice, serially transplanted every 7 days. Solid subcutaneous tumours, located dorsolaterally in mice, were initiated by an injection of 5 × 10 5 SA-1 cells in 0.1 ml 0.9% sodium chloride solution. The viability of the cells was over 95% as determined by the Trypan blue dye exclusion test. Six days after transplantation, when the tumours reached approximately 40 mm 3 in volume, mice were randomly divided into experimental groups, and subjected to a specific experimental protocol.
Electrochemotherapy protocol
cis-Diamminedichloroplatinum (II) (cisplatin) was obtained from Bristol Myers Squibb (Austria) as a crystalline powder and dissolved in sterile water at a concentration of 1 mg ml -1 . The final cisplatin solution was freshly prepared in 0.9% sodium chloride each day. Cisplatin at a dose of 4 mg kg -1 was injected intravenously into the retro-orbital sinus. Injection volume was 0.0075 ml g -1 body weight.
Eight square-wave electric pulses of 1040 V amplitude, with a pulse width of 100 µs and repetition frequency 1 Hz were delivered by two flat, parallel stainless-steel electrodes 8 mm apart (two stainless-steel strips: length 35 mm, width 7 mm with rounded corners), which were placed percutaneously at the opposite margins of the tumour. Good contact between the electrodes and the skin was assured by means of conductive gel. Electric pulses were generated by an electropulsator Jouan GHT 1287 (Saint Herblaine, France). In the electrochemotherapy protocol, mice were treated with electric pulses 3 min after cisplatin injection. All treatments were performed without anaesthesia and were well tolerated by the animals.
Tumour growth was followed by measuring three mutually orthogonal tumour diameters (e 1 , e 2 and e 3 ) with a vernier caliper on each consecutive day. Tumour volumes were calculated by the formula V = Π × e 1 × e 2 × e 3 /6. From these measurements, the arithmetic mean and standard error of the mean were calculated for each experimental group. Tumour growth delay was calculated for each individual tumour by subtracting the doubling time of each tumour from the mean doubling time of the control group and then averaged for each experimental group. Cell kill was calculated from the tumour growth curves using the formula: log 10 cell kill = tumour growth delay/3.32 × T d , in which 3.32 is the number of cell doublings per log of growth and T d is tumour doubling time (Corbett and Valeriote, 1987) .
Platinum determination in the tumours and DNA
To determine platinum content in the tumours and the amount of platinum bound to DNA, mice were sacrificed at various times after treatment with intravenously injected cisplatin and after electrochemotherapy. Tumours (six per group) were excised and removed from the overlying skin.
For platinum determination in whole tumour, each tumour was weighed (tumour weights were approximately 100 mg), placed into a 15-ml graduated polyethylene tube and digested in 1 ml of 65% nitric acid by incubation at 37°C for at least 2 days to obtain a clear solution. Samples were diluted with water to 10 ml before analysis.
For determination of the amount of platinum bound to DNA, each tumour was weighed, minced and treated with collagenase to obtain a single cell suspension. DNA was isolated using a modified salting out method (Miller et al, 1988) . Platinum content in the samples was determined by electrothermal atomic absorption spectrometry on a Hitachi Z-8270 Polarized Zeeman Atomic Absorption Spectrophotometer, adjusted to a wavelength of 265.9 nm (Milacic et al, 1997) .
Histology of tumours
The tumours from control, electric pulse, cisplatin-and electrochemotherapy-treated animals were excised 3 days after the treatment. Specimens were fixed immediately in 10% buffered neutral formalin. One tissue block cut through the largest diameter of the tumour was embedded in paraffin, and stained with haematoxylin-eosin by standard method. Slides of six tumours per group were examined in a blind fashion. Tumour necrosis was determined in whole mount tumour section through the largest tumour diameter.
Statistical analysis
The significance of differences between the mean values of tumour growth delays, degree of necrosis and platinum concentration of the experimental groups was evaluated by a modified t-test (Newman Keuls test), after a one-way analysis of variance was performed and fulfilled.
RESULTS
Anti-tumour effectiveness
Treatment of animals with cisplatin as a single treatment (4 mg kg -1 ) was ineffective and did not result in significant anti-tumour Figure 1 ). The treatment was well tolerated by the animals, body weight was not changed and no mortality was observed (data not shown). Electric pulses as a single treatment were moderately effective (Table 1, Figure 1 ). Tumour growth delay was significantly prolonged compared with the control, untreated group (P < 0.001). The application of electric pulses had no side-effects and no mortality of the animals was observed (data not shown).
Electrochemotherapy, combining intravenously injecting cisplatin (4 mg kg -1 ) with an application of eight electric pulses to the tumour (1040 V, 100 µs, 1 Hz) 3 min after the injection, was very effective (Table 1, Figure 1 ). The reduction of tumour volume was already detectable 3 days after the treatment. Thereafter, the tumours gradually decreased in size for up to 7 days, when they reached the pretreatment volume. Tumours were not exulcerated nor had superficial scab. Regrowth of the tumours was observed from the 8th day after the treatment. Their growth rate was approximately the same as in the control groups, but their growth was significantly delayed (P < 0.001) compared with control tumours or those treated with cisplatin and electric pulses as single treatment. Treatment with electrochemotherapy resulted in a log cell kill of 0.62 and was more than 20-fold higher than cell kill of cisplatin treatment alone (log cell kill = 0.03), as calculated from tumour growth curves. Electrochemotherapy treatment was well tolerated by the mice, body weight was not changed and no mortality was observed (data not shown).
Tumour platinum accumulation and amount of platinum bound to DNA
To determine whether the observed anti-tumour effectiveness of electrochemotherapy can be associated with increased cisplatin accumulation in the tumour cells, measurements of platinum content in the tumours and the amount of platinum bound to DNA were performed at different times after electrochemotherapy and cisplatin treatment. Platinum content in the tumour and DNA samples was determined by electrothermal atomic absorption spectrometry (Figure 2, Figure 3) . The initial level of platinum in whole tumours was the same in both groups, and wash out of platinum from the tumours was quick. However, significant (P < 0.008) differences in the platinum content between the two treatments was observed; after cisplatin treatment and electrochemotherapy, 50% of the initial level was obtained in 1 h and in 18 h respectively. At all time points except t = 0, the platinum content in the tumours treated by electrochemotherapy was approximately two times higher than in cisplatin-treated tumours (Figure 2) . Already 3 min after the treatment, two times higher amounts of platinum bound to DNA were detected in the tumours treated by electrochemotherapy than in the tumours treated by cisplatin alone. Thereafter, the amount of platinum bound to DNA in electrochemotherapy-treated tumours increased, reaching the maximum value 8 h after the treatment interval. This is in contrast to cisplatin-treated tumours, in which the amount of platinum bound to DNA was in the same range at all test times (Figure 3) . 
Degree of necrosis
Necrosis of tumour tissue was evaluated in controls and in all treatment groups 3 days after the beginning of treatment. The degree of necrosis estimated histologically is shown in Figure 4 . Cisplatin treatment did not result in significantly increased necrosis compared with controls. However, in tumours exposed to electric pulses and in tumours treated with electrochemotherapy, necrosis was increased significantly (P < 0.001). This degree of necrosis was the highest in tumours treated with electrochemotherapy (38.2% ± 2.2%). Histologically, necrosis in both control ( Figure 5 ) and cisplatintreated ( Figure 6 ) groups did not vary except for minor differences in the degree. Focal geographic necroses of tumour cells were characterized mostly by pyknosis, followed by coagulative type of necrosis with preservation of the basic outlines of the tumour cells. In the group treated with electric pulses, necrosis was advanced with large areas of coagulative necrosis with loss of cellular structures (Figure 7) . In tumours treated with electrochemotherapy, however, irreversible cell injury was manifested also by confluent areas of cells with distinct changes. Tumour cells were swollen with enlarged vesicular nuclei and solitary or multiple clumped nucleoplasmic condensations in granular background. Perinuclear cytoplasm was condensed, eosinophilic and filled with multiple blebs at the periphery of the cell (Figure 8 ).
DISCUSSION
Results of our study demonstrate that anti-tumour effectiveness of electrochemotherapy with cisplatin is associated with increased cisplatin accumulation in the tumours and increased amounts of platinum bound to DNA due to electroporation in vivo. In electrochemotherapy-treated tumours, more than twice the amount of platinum was determined in whole tumours, as well as on DNA compared with cisplatin-treated ones. Because electrochemotherapy produced a more than 20-fold increase in cell kill compared with cisplatin treatment alone, besides electroporation other mechanisms could also be involved in anti-tumour effectiveness of electrochemotherapy.
Electrochemotherapy with cisplatin has already been proven to be effective in treatment of different tumours, as demonstrated in preclinical Sersa et al, 1995 Sersa et al, , 1997 as well as in clinical studies (Sersa et al, 1998a) . However, it has not been demonstrated yet that the marked increase in anti-tumour effectiveness of cisplatin is due to the increased uptake of cisplatin by the tumour cells after application of electric pulses. Pharmacological studies of electrochemotherapy with belomycin, which is another drug used in electrochemotherapy, have already demonstrated that application of electric pulses to the tumours markedly increases drug accumulation in the tumours (Belehradek et al, 1994) . Our study was, thus, undertaken to confirm that cisplatin accumulation in the tumour cells after in vivo electrochemotherapy is also increased.
Cisplatin is a chemotherapeutic drug whose transport through the plasma membrane is restricted (Gately and Howell, 1993) . Bypassing the plasma membrane restriction by chemicals or electric pulses (Jekunen et al, 1993; Marverti et al, 1997; Melvik et al, 1986 could potentiate its anti-tumour effectiveness. Jekunen et al (1993) demonstrated that uptake of (Marverti et al, 1997) . In our previous study, we demonstrated that electroporation of B16 melanoma cells in vitro potentiated cisplatin cytotoxicity up to 70 times . Results of the present study demonstrate that tumour cell kill, platinum content in the tumours and the amount of platinum bound to DNA is increased in electrochemotherapy-treated tumours compared with cisplatin treatment alone. It is well known that DNA platination is the major cytotoxic lesion induced by cisplatin and responsible for cisplatin-induced cell death (Chu, 1994) . Therefore, from our results we can conclude that application of electric pulses to tumours in vivo increases the permeability of the plasma membrane of the cells and consequently enables cisplatin to enter the cells and bind to DNA. Other mechanisms that could contribute to the observed antitumour effectiveness of electrochemotherapy could be involvement of the immune system and modification of tumour blood flow due to the application of electric pulses. The role of the immune system in the anti-tumour effectiveness of electrochemotherapy with cisplatin has already been demonstrated . In that study, we have compared anti-tumour effectiveness of electrochemotherapy with cisplatin in immunocompetent and immunodeficient mice. We found that tumour growth delay in immunocompetent mice was approximately two times longer than in immunodeficient mice, and furthermore a high percentage of tumour cures was obtained in immunocompetent mice in contrast to immunodeficient in which none of the animals were cured. Thus, in the present study, the observed effectiveness of electrochemotherapy could be ascribed also to contribution of the immune system. After electrochemotherapy, less clonogenic tumour cells remain than after cisplatin treatment, therefore the immune system could be more effective in eradicating those cells.
Increased cell kill after electrochemotherapy as well as the observed plateau in the platinum accumulation curve of up to 8 h and the increase in the amount of platinum bound to DNA, with the maximum value at 8 h after the treatment interval, may partly be due to the vascular occlusion in the tumours exposed to electric pulses. As observed in our previous study, besides electroporation, electric pulses can modify tumour blood flow (Sersa et al, 1998b) . Application of electric pulses such as those used in this study reduce tumour blood flow by 60-70% and result in a tumour growth delay of 0.2 days. The changes in blood flow are transient, lasting for 1 h, thereafter tumour blood flow steadily recovers to almost normal levels within 24 h. Having this in mind, the observed retention of platinum in the tumours and increase in DNA platination up to 8 h after the application of electric pulses may be, in addition to electroporation, due to the blood-modifying effect of electric pulses.
Morphological changes in the tumours correlate well with data on anti-tumour effectiveness. Degree of tumour necrosis follows the anti-tumour effectiveness of each therapeutic approach, electrochemotherapy being the most successful. Specifically, morphological changes of tumour cells in tumours treated with electrochemotherapy were different and greater in extent than in tumours treated with cisplatin only.
In conclusion, our study provides evidence that electroporation of tumours in vivo increases uptake of cisplatin in cells. Electrochemotherapy with cisplatin has already been tested in a clinical trial on malignant melanoma, squamous cell carcinoma and basal cell carcinoma (Sersa et al, 1998a) . Therefore, this study further supports this therapy by providing evidence of its underlying mechanisms. 
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